Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38021   clinical trials with a EudraCT protocol, of which   6240   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del-CFTR Mutation

    Summary
    EudraCT number
    2017-000540-18
    Trial protocol
    FR   DE  
    Global end of trial date
    09 Aug 2018

    Results information
    Results version number
    v2(current)
    This version publication date
    03 Jan 2020
    First version publication date
    24 Feb 2019
    Other versions
    v1
    Version creation reason
    • New data added to full data set
    Addition of Secondary Endpoints

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    VX16-661-114
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03150719
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Vertex Pharmaceuticals Incorporated
    Sponsor organisation address
    50 Northern Avenue, Boston, United States,
    Public contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617-341-6777, medicalinfo@vrtx.com
    Scientific contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617-341-6777, medicalinfo@vrtx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    27 Aug 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    09 Aug 2018
    Global end of trial reached?
    Yes
    Global end of trial date
    09 Aug 2018
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the respiratory safety of Tezacaftor/Ivacaftor (TEZ/IVA) in subjects with Cystic Fibrosis homozygous for F508del mutation of the CFTR gene that previously discontinued Lumacaftor/Ivacaftor (LUM/IVA) due to treatment-related respiratory signs or symptoms
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    24 May 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 49
    Country: Number of subjects enrolled
    France: 12
    Country: Number of subjects enrolled
    Germany: 37
    Worldwide total number of subjects
    98
    EEA total number of subjects
    49
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    1
    Adults (18-64 years)
    97
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 98 subjects were randomized: 47 in placebo group and 51 in TEZ/IVA group. One subject in TEZ/IVA group did not receive any study drug.

    Period 1
    Period 1 title
    Overall Trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Subjects received placebo matched to TEZ/IVA fixed dose combination (FDC) once daily in the morning followed by placebo matched to IVA once daily in the evening for 56 days.
    Arm type
    Experimental

    Investigational medicinal product name
    Placebo (matched to TEZ/IVA)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to TEZ/IVA FDC once daily in the morning for 56 days.

    Investigational medicinal product name
    Placebo (matched to IVA)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to IVA once daily in the evening for 56 days.

    Arm title
    TEZ/IVA
    Arm description
    Subjects received TEZ/IVA FDC once daily in the morning followed by IVA once daily in the evening for 56 days.
    Arm type
    Experimental

    Investigational medicinal product name
    TEZ/IVA
    Investigational medicinal product code
    VX-661/VX-770
    Other name
    Tezacaftor/Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received 100 milligram (mg) TEZ/ 150 mg IVA FDC once daily in the morning for 56 days.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received 150 mg IVA once daily in the evening for 56 days.

    Number of subjects in period 1 [1]
    Placebo TEZ/IVA
    Started
    47
    50
    Completed
    46
    48
    Not completed
    1
    2
         Death
    -
    1
         Other
    1
    -
         Adverse Event
    -
    1
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: A total of 98 subjects were randomized: 47 in placebo group and 51 in TEZ/IVA group. One subject in TEZ/IVA group did not receive any study drug.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to TEZ/IVA fixed dose combination (FDC) once daily in the morning followed by placebo matched to IVA once daily in the evening for 56 days.

    Reporting group title
    TEZ/IVA
    Reporting group description
    Subjects received TEZ/IVA FDC once daily in the morning followed by IVA once daily in the evening for 56 days.

    Reporting group values
    Placebo TEZ/IVA Total
    Number of subjects
    47 50 97
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    33.3 ± 10.0 34.3 ± 8.7 -
    Gender categorical
    Units: Subjects
        Female
    30 31 61
        Male
    17 19 36
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    3 1 4
        Not Hispanic or Latino
    40 41 81
        Unknown or Not Reported
    4 8 12
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0
        Asian
    0 0 0
        Native Hawaiian or Other Pacific Islander
    0 0 0
        Black or African American
    1 0 1
        White
    42 42 84
        More than one race
    0 0 0
        Unknown or Not Reported
    4 8 12

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to TEZ/IVA fixed dose combination (FDC) once daily in the morning followed by placebo matched to IVA once daily in the evening for 56 days.

    Reporting group title
    TEZ/IVA
    Reporting group description
    Subjects received TEZ/IVA FDC once daily in the morning followed by IVA once daily in the evening for 56 days.

    Primary: Incidence of Respiratory Adverse Events of Special Interest (RAESIs)

    Close Top of page
    End point title
    Incidence of Respiratory Adverse Events of Special Interest (RAESIs) [1]
    End point description
    RAESIs included chest discomfort, dyspnea (shortness of breath), respiration abnormal (chest tightness), asthma, bronchial hyperreactivity, bronchospasm, and wheezing.
    End point type
    Primary
    End point timeframe
    Day 1 up to Day 84
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned. No statistical comparisons were planned for primary safety endpoint.
    End point values
    Placebo TEZ/IVA
    Number of subjects analysed
    47
    50
    Units: Subjects
    10
    7
    No statistical analyses for this end point

    Secondary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Day 28 and Day 56 Measurements

    Close Top of page
    End point title
    Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Day 28 and Day 56 Measurements
    End point description
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 28 and Day 56
    End point values
    Placebo TEZ/IVA
    Number of subjects analysed
    47
    50
    Units: percent predicted of FEV1
        arithmetic mean (standard deviation)
    -0.6 ± 3.4
    2.2 ± 4.8
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    TEZ/IVA v Placebo
    Number of subjects included in analysis
    97
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Mean Difference
    Point estimate
    2.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1
         upper limit
    4.4

    Secondary: Relative Change From Baseline in ppFEV1 at Average of Day 28 and Day 56 Measurements

    Close Top of page
    End point title
    Relative Change From Baseline in ppFEV1 at Average of Day 28 and Day 56 Measurements
    End point description
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 28 and Day 56
    End point values
    Placebo TEZ/IVA
    Number of subjects analysed
    47
    50
    Units: percent change
        arithmetic mean (standard deviation)
    -1.5 ± 8.1
    5.2 ± 12.0
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    Placebo v TEZ/IVA
    Number of subjects included in analysis
    97
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Mean Difference
    Point estimate
    6.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    2.5
         upper limit
    10.9

    Secondary: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Day 28 and Day 56 Measurements

    Close Top of page
    End point title
    Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Average of Day 28 and Day 56 Measurements
    End point description
    The CFQ-R is a validated subject-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
    End point type
    Secondary
    End point timeframe
    Baseline, Day 28 and Day 56
    End point values
    Placebo TEZ/IVA
    Number of subjects analysed
    47
    50
    Units: units on a scale
        arithmetic mean (standard deviation)
    4.7 ± 15.4
    5.7 ± 14.2
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    Placebo v TEZ/IVA
    Number of subjects included in analysis
    97
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Mean Difference
    Point estimate
    1.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.9
         upper limit
    7

    Secondary: Tolerability as Assessed by Number of Subjects Who Discontinued Treatment

    Close Top of page
    End point title
    Tolerability as Assessed by Number of Subjects Who Discontinued Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    Day 1 through Day 56
    End point values
    Placebo TEZ/IVA
    Number of subjects analysed
    47
    50
    Units: subjects
    2
    2
    No statistical analyses for this end point

    Secondary: Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Close Top of page
    End point title
    Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
    End point description
    End point type
    Secondary
    End point timeframe
    Day 1 up to Day 84
    End point values
    Placebo TEZ/IVA
    Number of subjects analysed
    47
    50
    Units: subjects
        Subjects with AEs
    39
    37
        Subjects with SAEs
    9
    5
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Day 1 up to Day 84
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    21.0
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to TEZ/IVA fixed dose combination (FDC) once daily in the morning followed by placebo matched to IVA once daily in the evening for 56 days.

    Reporting group title
    TEZ/IVA
    Reporting group description
    Subjects received TEZ/IVA FDC once daily in the morning followed by IVA once daily in the evening for 56 days.

    Serious adverse events
    Placebo TEZ/IVA
    Total subjects affected by serious adverse events
         subjects affected / exposed
    9 / 47 (19.15%)
    5 / 50 (10.00%)
         number of deaths (all causes)
    0
    1
         number of deaths resulting from adverse events
    Cardiac disorders
    Pericardial effusion
         subjects affected / exposed
    1 / 47 (2.13%)
    0 / 50 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pleuritic pain
         subjects affected / exposed
    1 / 47 (2.13%)
    0 / 50 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    0 / 47 (0.00%)
    1 / 50 (2.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Psychiatric disorders
    Suicidal ideation
         subjects affected / exposed
    0 / 47 (0.00%)
    1 / 50 (2.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    0 / 47 (0.00%)
    1 / 50 (2.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Musculoskeletal chest pain
         subjects affected / exposed
    1 / 47 (2.13%)
    0 / 50 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    7 / 47 (14.89%)
    3 / 50 (6.00%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 47 (0.00%)
    1 / 50 (2.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 47 (2.13%)
    0 / 50 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo TEZ/IVA
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    28 / 47 (59.57%)
    30 / 50 (60.00%)
    Investigations
    Bacterial test positive
         subjects affected / exposed
    0 / 47 (0.00%)
    3 / 50 (6.00%)
         occurrences all number
    0
    3
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    8 / 47 (17.02%)
    9 / 50 (18.00%)
         occurrences all number
    8
    9
    Dyspnoea
         subjects affected / exposed
    5 / 47 (10.64%)
    5 / 50 (10.00%)
         occurrences all number
    5
    5
    Haemoptysis
         subjects affected / exposed
    2 / 47 (4.26%)
    3 / 50 (6.00%)
         occurrences all number
    2
    3
    Respiration abnormal
         subjects affected / exposed
    1 / 47 (2.13%)
    3 / 50 (6.00%)
         occurrences all number
    1
    3
    Oropharyngeal pain
         subjects affected / exposed
    3 / 47 (6.38%)
    2 / 50 (4.00%)
         occurrences all number
    3
    2
    Sputum increased
         subjects affected / exposed
    5 / 47 (10.64%)
    2 / 50 (4.00%)
         occurrences all number
    5
    2
    Nervous system disorders
    Headache
         subjects affected / exposed
    7 / 47 (14.89%)
    6 / 50 (12.00%)
         occurrences all number
    11
    6
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    4 / 47 (8.51%)
    2 / 50 (4.00%)
         occurrences all number
    4
    2
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    5 / 47 (10.64%)
    4 / 50 (8.00%)
         occurrences all number
    9
    4
    Constipation
         subjects affected / exposed
    0 / 47 (0.00%)
    4 / 50 (8.00%)
         occurrences all number
    0
    4
    Nausea
         subjects affected / exposed
    2 / 47 (4.26%)
    4 / 50 (8.00%)
         occurrences all number
    2
    5
    Diarrhoea
         subjects affected / exposed
    3 / 47 (6.38%)
    1 / 50 (2.00%)
         occurrences all number
    3
    1
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    3 / 47 (6.38%)
    1 / 50 (2.00%)
         occurrences all number
    3
    1
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    0 / 47 (0.00%)
    6 / 50 (12.00%)
         occurrences all number
    0
    6
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    9 / 47 (19.15%)
    4 / 50 (8.00%)
         occurrences all number
    10
    4

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Apr 2017
    Revised sample size, and the time from Orkambi initiation to discontinuation; Additional safety measures added; Subjects who completed Day 56 Visit were given the opportunity to enroll in a long-term, open-label safety study of TEZ/IVA
    09 Jun 2017
    Added post-dose spirometry on Day 1 for additional safety; Clarified the visits for pulse oximetry and vital sign assessments; Removed restrictions on the concomitant use of corticosteroids

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA